SCHEMBL4110282

SCHEMBL4110282

COc1cccc(C(=O)c2cc(Cl)cc(F)c2-n2cccc2)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TUBB4A P04350 9/20 0.40
TUBB P07437 9/20 0.40
TUBA3C P0DPH7 9/20 0.40
TUBA1B P68363 9/20 0.40
TUBA4A P68366 9/20 0.40
TUBB4B P68371 9/20 0.40
TUBB3 Q13509 9/20 0.40
TUBB2A Q13885 9/20 0.40
TUBB8 Q3ZCM7 9/20 0.40
TUBA3E Q6PEY2 9/20 0.40
TUBA1A Q71U36 9/20 0.40
TUBA1C Q9BQE3 9/20 0.40
TUBB6 Q9BUF5 9/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118523 0.86 TUBB4A (0.39) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4133226 0.82 GAA (0.45) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4119074 0.80 NPC1 (0.47) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4122687 0.80 L3MBTL1 (0.44) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4127985 0.79 RAB9A (0.36) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4127982 0.79 RAB9A (0.36) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4119220 0.77 RAB9A (0.41) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1
SCHEMBL4118982 0.75 LMNA (0.41) KDM4EALDH1A1LMNANPSR1TUBB4A
SCHEMBL4117279 0.75 MAPT (0.43) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3762150 0.74 RAB9A (0.55) RAB9ASMN1; SMN2NPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR RAB9A 4041/4885SMN1; SMN2 4445/4885NPC1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.